Home/Filings/4/0001274737-22-000083
4//SEC Filing

ABALLI JOHN 4

Accession 0001274737-22-000083

CIK 0001274737other

Filed

Dec 8, 7:00 PM ET

Accepted

Dec 9, 9:00 AM ET

Size

5.0 KB

Accession

0001274737-22-000083

Insider Transaction Report

Form 4
Period: 2022-12-08
ABALLI JOHN
DirectorPresident and CEO
Transactions
  • Purchase

    Common Stock

    2022-12-08$2.68/sh+90,000$241,200440,000 total
Footnotes (1)
  • [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.34 to $2.75, inclusive. The reporting person undertakes to provide Exagen Inc., any security holder of Exagen Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this form 4.

Issuer

EXAGEN INC.

CIK 0001274737

Entity typeother

Related Parties

1
  • filerCIK 0001843113

Filing Metadata

Form type
4
Filed
Dec 8, 7:00 PM ET
Accepted
Dec 9, 9:00 AM ET
Size
5.0 KB